ArticleFrontiers in aging neuroscience2018
Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program.
Article in Frontiers in aging neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Study of blood linear RNA nominates CD55 and DLD as early-stage biomarkers for Parkinson's disease.Brain : a journal of neurology · 2026Article
- Exome sequencing and metabolite profiling identifies genetic variants associated with altered metabolism in early-onset schizophrenia.iScience · 2026Article
- Parallel Single-Tissue Summary-Data Mendelian Randomization and Functional Validation Identify the ARRDC1 Promoter SNP rs4494021 as a Genetic Marker Associated with Anxiety Disorders.Neuropsychiatric disease and treatment · 2026Article
- Summarizing the Role of Selected Adipokines in Parkinson's Disease: What Is Known About Leptin, Adiponectin, Resistin, Visfatin, and Progranulin in Neurodegeneration?Molecules (Basel, Switzerland) · 2025Review
- Article
- Urea Transporters and Their Gene Mutations in Diseases.Sub-cellular biochemistry · 2025Review
- Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Early-stage idiopathic Parkinson's disease is associated with reduced circular RNA expression.NPJ Parkinson's disease · 2024Article
- Molecular Gene Expression Testing to Identify Alzheimer's Disease with High Accuracy from Fingerstick Blood.Journal of Alzheimer's disease : JAD · 2024Article
- Role of Non-Receptor-Type Tyrosine Phosphatases in Brain-Related Diseases.Molecular neurobiology · 2023Review
- Molecular Mechanisms for Changing Brain Connectivity in Mice and Humans.International journal of molecular sciences · 2023Article
- Exploring the association of addiction-related genetic factors with non-suicidal self-injury in adolescents.Frontiers in psychiatry · 2023Article
- Systemic RNA Interference Defective (SID) genes modulate dopaminergic neurodegeneration in C. elegans.PLoS genetics · 2022Article
- Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.Diagnostics (Basel, Switzerland) · 2022Review
- A review of migraine genetics: gathering genomic and transcriptomic factors.Human genetics · 2022Review
- Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.Diagnostics (Basel, Switzerland) · 2020Review
- Osmotic regulation of UT-B urea transporters in the RT4 human urothelial cell line.Physiological reports · 2019Article
- Unequivocal Biomarker for Parkinson's Disease: A Hunt that Remains a Pester.Neurotoxicity research · 2019Review
- Biomarkers of Parkinson's disease: 20 years later.Journal of neural transmission (Vienna, Austria : 1996) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
There is a high misdiagnosis rate between Parkinson's disease (PD) and atypical parkinsonian disorders (APD), such as progressive supranuclear palsy (PSP), the second most common parkinsonian syndrome. In our earlier studies, we identified and replicated RNA blood biomarkers in several independent cohorts, however, replication in a cohort that includes PSP patients has not yet been performed. To this end, we evaluated the diagnostic potential of nine previously identified RNA biomarkers using quantitative PCR assays in 138 blood samples at baseline from PD, PSP and healthy controls (HCs) nested in the PD Biomarkers Program. Linear discriminant analysis showed that
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.